ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 177

Treatment with Dexamethasone and Monophosphoryl Lipid a Removes Disease-Associated Transcriptional Signatures in Monocyte-Derived Dendritic Cells from Rheumatoid Arthritis Patients and Confers the Ability to Modulate CD4+ T Cell Responses

Paulina García-González1,2, Oscar Neira3, Katina Schinnerling1,2, Alejandro Sepúlveda-Gutiérrez4, Jaxaira Maggy1,2, Lorena Hoyos1,2, Rodrigo Morales1,2, Gabriela Ubilla-Olguín1,2, Ahmed Mehdi5, Hendrik Nel6, Lilian Soto1,7, Bárbara Pesce1,2, María Carmen Molina1, Miguel Cuchacovich8, Milton Larrondo9, Diego Catalán1,2, Catharien M. Hilkens10, Ranjeny Thomas11, Ricardo Verdugo4 and Juan C. Aguillón1,2, 1Programa Disciplinario de Inmunología, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile, Santiago, Chile, 2Millennium Institute on Immunology and Immunotherapy, Santiago, Chile, Santiago, Chile, 3Rheumatology Unit, Hospital del Salvador. Facultad de Medicina. Universidad de Chile, Santiago, Chile, 4Programa de Genética Humana, ICBM, Universidad de Chile, Santiago, Chile, Santiago, Chile, 5Diamantina Institute, The University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Australia, 6The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, 7Unidad de Dolor, Hospital Clínico de la Universidad de Chile, Santiago, Chile, Santiago, Chile, 8Sección de Reumatología, Departamento de Medicina, Hospital Clínico de la Universidad de Chile, Santiago, Chile, 9Banco de Sangre, Hospital Clínico Universidad de Chile, Santiago, Chile, Santiago, Chile, 10Institute of Cellular Medicine, Musculoskeletal Research Group, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK., Newcastle upon Tyne,, United Kingdom, 11The University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Australia

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Cell therapy, Dendritic cells, rheumatoid arthritis (RA) and tolerance

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Innate Immunity and Rheumatic Disease - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Tolerogenic dendritic cells (TolDCs) are promising tools for therapy of autoimmune diseases such as rheumatoid arthritis (RA). Here we characterise TolDCs from RA patients modulated with dexamethasone and monophosphoryl lipid A (MPLA) concerning gene expression, phenotype, cytokine profile, migratory properties and T cell-stimulatory capacity to explore their suitability for autologous cellular therapy.

Methods: TolDCs were generated from monocytes of 9 RA patients, meeting 2010 ACR/EULAR criteria, and 10 healthy controls, using dexamethasone for tolerization and MPLA for activation (MPLA-tDCs). The phenotype of MPLA-tDCs and their migratory behaviour towards lymphoid chemokines were analysed by flow cytometry and transwell assays. Cytokine secretion of MPLA-tDCs and their ability to activate autologous antigen-specific T cells was determined by flow cytometry and ELISA. Genome-wide transcriptional analysis was performed and differential expression was defined by a false discovery rate of ≤ 0.05.

Results: MPLA-tDCs derived from RA patients, exhibited characteristics of semi-mature DCs (Fig 1), such as: reduced expression of costimulatory and coactivation molecules and the capacity to migrate in response to ligands of lymph node homing chemokine receptors CCR7 and CXCR4. These cells displayed an anti-inflammatory cytokine profile inducing hyporesponsiveness and IL-10 secretion of autologous CD4+ T cells specific to synovial antigens. Global transcriptome analysis demonstrated that treatment with dexamethasone and MPLA overcame RA-associated effects on gene expression profiles of monocyte-derived DCs (Fig 2). Figure 1.pdf Figure 1. MPLA-tDCs from rheumatoid arthritis patients and healthy controls display low expression of maturation markers and high TLR2.   160317_Figure 5.pdf Figure 2. Conditioning with dexamethasone and MPLA induces similar transcriptional profiles on moDCs from RA patients and healthy controls, and reverses disease-associated effects on gene expression in MPLA-tDCs derived from monocytes of rheumatoid arthritis patients  

Conclusion: Monocyte-derived DCs of RA patients have the potential to develop stable tolerogenic features when modulated with dexamethasone and MPLA, irrespective of disease status. The ability of MPLA-tDCs to impair T cell responses to synovial antigens validates their potential for the treatment of RA. Funding:  Fondecyt-Chile 1100102 and 1140553, and Millennium Institute on Immunology and Immunotherapy P09-016-F.  


Disclosure: P. García-González, None; O. Neira, None; K. Schinnerling, None; A. Sepúlveda-Gutiérrez, None; J. Maggy, None; L. Hoyos, None; R. Morales, None; G. Ubilla-Olguín, None; A. Mehdi, None; H. Nel, None; L. Soto, None; B. Pesce, None; M. C. Molina, None; M. Cuchacovich, None; M. Larrondo, None; D. Catalán, None; C. M. Hilkens, None; R. Thomas, None; R. Verdugo, None; J. C. Aguillón, None.

To cite this abstract in AMA style:

García-González P, Neira O, Schinnerling K, Sepúlveda-Gutiérrez A, Maggy J, Hoyos L, Morales R, Ubilla-Olguín G, Mehdi A, Nel H, Soto L, Pesce B, Molina MC, Cuchacovich M, Larrondo M, Catalán D, Hilkens CM, Thomas R, Verdugo R, Aguillón JC. Treatment with Dexamethasone and Monophosphoryl Lipid a Removes Disease-Associated Transcriptional Signatures in Monocyte-Derived Dendritic Cells from Rheumatoid Arthritis Patients and Confers the Ability to Modulate CD4+ T Cell Responses [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/treatment-with-dexamethasone-and-monophosphoryl-lipid-a-removes-disease-associated-transcriptional-signatures-in-monocyte-derived-dendritic-cells-from-rheumatoid-arthritis-patients-and-confers-the-abi/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-with-dexamethasone-and-monophosphoryl-lipid-a-removes-disease-associated-transcriptional-signatures-in-monocyte-derived-dendritic-cells-from-rheumatoid-arthritis-patients-and-confers-the-abi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology